Answers are grounded in this paper and cite their sources.
Purpose We compared perioperative bleeding morbidity after primary transurethral resection of the prostate (TURP) versus repeat TURP (re-TURP) to inform counseling and risk stratification. Methods We queried the American College of Surgeons National Surgical Quality Improvement Program (2013–2023) for primary TURP (Current Procedural Terminology [CPT] 52601) and re-TURP (CPT 52630). The primary outcome was perioperative transfusion. Secondary outcomes included ICD-10-based hematuria endpoints from postoperative, readmission, and reoperation diagnoses, as well as reoperation CPT categories. Multivariable logistic models adjusted for age, ASA class, bleeding disorder, urinary tract infection, hematocrit, and platelet count; additional models included surgical urgency, operative time, INR, and albumin. Results We identified 83,539 procedures: 76,983 primary TURPs and 6,556 re-TURPs. Transfusion occurred in 1.5% after primary TURP versus 1.9% after re-TURP, while hematuria-related postoperative diagnoses accounted for 1.3% versus 3.6%. Re-TURP was associated with hematuria-related postoperative diagnoses after adjustment (adjusted odds ratio [aOR] 2.70, 95% CI 2.27–3.21), whereas its adjusted association with transfusion was nonsignificant (aOR 1.12, 95% CI 0.90–1.39). Older age, bleeding disorder, lower hematocrit, and lower platelet count were associated with both bleeding outcomes. Findings were consistent across sensitivity analyses. Hematuria was the largest recorded readmission and reoperation diagnosis group, and clot evacuation/fulguration/irrigation was the largest reoperation procedure category in both cohorts, without significant between-group differences. Conclusions Re-TURP was associated with greater odds of a recorded hematuria-related postoperative diagnosis, while its adjusted association with transfusion was not statistically significant. Because diagnosis codes cannot establish bleeding severity or onset, these findings require confirmation using clinically validated bleeding endpoints.
No takes yet. Share an insight, caveat, or question.
Derigs et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: